(See also Overview of Thyroid Function.)
Hypothyroidism occurs at any age but is particularly common among older adults, where it may present subtly and be difficult to recognize. Hypothyroidism may be
Primary hypothyroidism is due to disease in the thyroid; thyroid-stimulating hormone (TSH) is increased. The most common cause is autoimmune. It usually results from Hashimoto thyroiditis and is often associated with a firm goiter or, later in the disease process, with a shrunken fibrotic thyroid with little or no function. The 2nd most common cause is post-therapeutic hypothyroidism, especially after radioactive iodine therapy or surgery for hyperthyroidism or goiter. Hypothyroidism during overtreatment with propylthiouracil, methimazole, and iodide abates after therapy is stopped.
Most patients with non-Hashimoto goiters are euthyroid or have hyperthyroidism, but goitrous hypothyroidism may occur in endemic goiter due to iodine deficiency. Iodine deficiency decreases thyroid hormonogenesis. In response, TSH is released, which causes the thyroid to enlarge and trap iodine avidly; thus, goiter results. If iodine deficiency is severe, the patient becomes hypothyroid, a rare occurrence in the United States since the advent of iodized salt.
Iodine deficiency can cause congenital hypothyroidism. In severely iodine-deficient regions worldwide, congenital hypothyroidism (previously termed endemic cretinism) is a major cause of intellectual disability.
Rare inherited enzymatic defects can alter the synthesis of thyroid hormone and cause goitrous hypothyroidism.
Hypothyroidism may occur in patients taking lithium, perhaps because lithium inhibits hormone release by the thyroid. Hypothyroidism may also occur in patients taking amiodarone or other iodine-containing drugs, in patients taking interferon-alfa, and in patients taking checkpoint inhibitors or some tyrosine kinase inhibitors for cancer. Hypothyroidism can result from radiation therapy for cancer of the larynx or Hodgkin lymphoma. The incidence of permanent hypothyroidism after radiation therapy is high, and thyroid function (through measurement of serum TSH) should be evaluated at 6- to 12-month intervals.
Subclinical hypothyroidism is elevated serum TSH in patients with absent or minimal symptoms of hypothyroidism and normal serum levels of free thyroxine (T4).
Subclinical thyroid dysfunction is relatively common; it occurs in about 15% of older women and 10% of older men, particularly in those with underlying Hashimoto thyroiditis.
In patients with serum TSH > 10 mU/L, there is a high likelihood of progression to overt hypothyroidism with low serum levels of free T4 within the next 10 years. These patients are also more likely to have hypercholesterolemia and atherosclerosis. They should be treated with l-thyroxine, even if they are asymptomatic.
For patients with TSH levels between 4.5 and 10 mU/L, a trial of l-thyroxine is reasonable if symptoms of early hypothyroidism (eg, fatigue, depression) are present.
l-Thyroxine therapy is also indicated in pregnant women and in women who plan to become pregnant to avoid deleterious effects of hypothyroidism on the pregnancy and fetal development. Patients should have annual measurement of serum TSH and free T4 to assess progress of the condition if untreated or to adjust the l-thyroxine dosage.
Symptoms and signs of primary hypothyroidism are often subtle and insidious. Various organ systems may be affected.
Metabolic manifestations: Cold intolerance, modest weight gain (due to fluid retention and decreased metabolism), hypothermia
Neurologic manifestations: Forgetfulness, paresthesias of the hands and feet (often due to carpal tunnel syndrome caused by deposition of proteinaceous ground substance in the ligaments around the wrist and ankle); slowing of the relaxation phase of deep tendon reflexes
Psychiatric manifestations: Personality changes, depression, dull facial expression, dementia or frank psychosis (myxedema madness)
Dermatologic manifestations: Facial puffiness; myxedema; sparse, coarse and dry hair; coarse, dry, scaly and thick skin; carotenemia, particularly notable on the palms and soles (caused by deposition of carotene in the lipid-rich epidermal layers); macroglossia due to deposition of proteinaceous ground substance in the tongue
Ocular manifestations: Periorbital swelling due to infiltration with the mucopolysaccharides hyaluronic acid and chondroitin sulfate), droopy eyelids because of decreased adrenergic drive
Gastrointestinal manifestations: Constipation
Gynecologic manifestations: Menorrhagia or secondary amenorrhea
Cardiovascular manifestations: Slow heart rate (a decrease in both thyroid hormone and adrenergic stimulation causes bradycardia), enlarged heart on examination and imaging (partly because of dilation but chiefly because of pericardial effusion; pericardial effusions develop slowly and only rarely cause hemodynamic distress)
Other manifestations: Pleural or abdominal effusions (pleural effusions develop slowly and only rarely cause respiratory or hemodynamic distress), hoarse voice, and slow speech
Symptoms can differ significantly in older patients.
Although secondary hypothyroidism is uncommon, its causes often affect other endocrine organs controlled by the hypothalamic-pituitary axis. In a woman with hypothyroidism, indications of secondary hypothyroidism are a history of amenorrhea rather than menorrhagia and some suggestive differences on physical examination.
Secondary hypothyroidism is characterized by skin and hair that are dry but not very coarse, skin depigmentation, only minimal macroglossia, atrophic breasts, and low blood pressure. Also, the heart is small, and serous pericardial effusions do not occur. Hypoglycemia is common because of concomitant adrenal insufficiency or growth hormone deficiency.
Myxedema coma is a life-threatening complication of hypothyroidism, usually occurring in patients with a long history of hypothyroidism. Its characteristics include coma with extreme hypothermia (temperature 24° to 32.2° C), areflexia, seizures, and respiratory depression with carbon dioxide retention. Severe hypothermia may be missed unless low-reading thermometers are used. Rapid diagnosis based on clinical judgment, history, and physical examination is imperative, because death is likely without rapid treatment. Precipitating factors include illness, infection, trauma, drugs that suppress the central nervous system, and exposure to cold.
Serum thyroid-stimulating hormone measurement is the most sensitive test for diagnosing hypothyroidism. In primary hypothyroidism, there is no feedback inhibition of the intact pituitary, and serum TSH is always elevated, whereas serum free T4 is low. In secondary hypothyroidism, free T4 and serum TSH are low (sometimes TSH is normal but with decreased bioactivity).
Many patients with primary hypothyroidism have normal circulating levels of triiodothyronine (T3), probably caused by sustained TSH stimulation of the failing thyroid, resulting in preferential synthesis and secretion of biologically active T3. Therefore, serum T3 is not sensitive for hypothyroidism.
Anemia is often present, usually normocytic-normochromic and of unknown etiology, but it may be hypochromic because of menorrhagia and sometimes macrocytic because of associated pernicious anemia or decreased absorption of folate. Anemia is rarely severe (hemoglobin usually > 9 g/dL or 90 g/L). As the hypometabolic state is corrected, anemia subsides, sometimes requiring 6 to 9 months.
Serum cholesterol is usually high in primary hypothyroidism but less so in secondary hypothyroidism.
Screening for hypothyroidism is warranted in select populations (eg, older adults), in which it is relatively more prevalent, especially because its manifestations can be subtle. Screening is done by measuring TSH levels.
Various thyroid hormone preparations are available for replacement therapy, including synthetic preparations of T4 (l-thyroxine [levothyroxine]), T3 (liothyronine), combinations of the 2 synthetic hormones, and desiccated animal thyroid extract. L-Thyroxine is preferred; the usual maintenance dose is 75 to 150 mcg orally once a day, depending on age, body mass index, and absorption (for pediatric doses, see Hypothyroidism in Infants and Children). The starting dose in young or middle-aged patients who are otherwise healthy can be 100 mcg or 1.7 mcg/kg orally once a day.
However, in patients with heart disease, therapy is begun with low doses, usually 25 mcg once a day. The dose is adjusted every 6 weeks until maintenance dose is achieved. The maintenance dose may need to be increased in pregnant women. Dose may also need to be increased if drugs that decrease T4 absorption or increase its metabolic clearance are administered concomitantly. The dose used should be the lowest that restores serum TSH levels to the midnormal range (though this criterion cannot be used in patients with secondary hypothyroidism). In secondary hypothyroidism the dose of L-thyroxine should achieve a free T4 level in the midnormal range.
Liothyronine (L-triiodothyronine) should not be used alone for long-term replacement because of its short half-life and the large peaks in serum T3 levels it produces. The administration of standard replacement amounts (25 to 37.5 mcg twice a day) results in rapidly increasing serum T3 to between 300 and 1000 ng/dL (4.62 to 15.4 nmol/L) within 4 hours due to its almost complete absorption; these levels return to normal by 24 hours. Additionally, patients receiving liothyronine are chemically hyperthyroid for at least several hours a day, potentially increasing cardiac risks.
Similar patterns of serum T3 changes occur when mixtures of T3 and T4 are taken orally, although peak T3 is lower because less T3 is given. Replacement regimens with synthetic T4 preparations reflect a different pattern in serum T3 response. Increases in serum T3 occur gradually, and normal levels are maintained when adequate doses of T4 are given. Desiccated animal thyroid preparations contain variable amounts of T3 and T4 and should not be prescribed unless the patient is already taking the preparation and has normal serum TSH.
In patients with secondary hypothyroidism, l-thyroxine should not be given until there is evidence of adequate cortisol secretion (or cortisol therapy is given), because l-thyroxine could precipitate adrenal crisis.
Myxedema coma is treated as follows:
Patients require a large initial dose of T4 (300 to 500 mcg IV) or T3 (25 to 50 mcg IV). The intravenous maintenance dose of T4 is 75 to 100 mcg once a day and of T3, 10 to 20 mcg twice a day until T4 can be given orally. Corticosteroids are also given because the possibility of central hypothyroidism usually cannot be initially ruled out. The patient should not be rewarmed rapidly, which may precipitate hypotension or arrhythmias.
Hypoxemia is common, so PaO2 should be monitored. If ventilation is compromised, immediate mechanical ventilatory assistance is required. The precipitating factor should be rapidly and appropriately treated and fluid replacement given carefully, because hypothyroid patients do not excrete water appropriately. Finally, all drugs should be given cautiously because they are metabolized more slowly than in healthy people.
Hypothyroidism is particularly common among older adults. It occurs in close to 10% of women and 6% of men > 65. Although typically easy to diagnose in younger adults, hypothyroidism may be subtle and manifest atypically in older adults.
Older patients have significantly fewer symptoms than do younger adults, and complaints are often subtle and vague. Many older patients with hypothyroidism present with nonspecific geriatric syndromes—confusion, anorexia, weight loss, falling, incontinence, and decreased mobility. Musculoskeletal symptoms (especially arthralgias) occur often, but arthritis is rare. Muscular aches and weakness, often mimicking polymyalgia rheumatica or polymyositis, and an elevated creatine kinase (CK) level may occur. In older patients, hypothyroidism may mimic dementia or parkinsonism.
In older patients, l-thyroxine therapy is begun with low doses, usually 25 mcg once a day. Maintenance doses may also need to be lower in older patients.
Primary hypothyroidism is most common; it is due to disease in the thyroid, and thyroid-stimulating hormone (TSH) levels are high.
Secondary hypothyroidism is less common; it is due to pituitary or hypothalamic disease, and TSH levels are low.
Symptoms develop insidiously and typically include cold intolerance, constipation, and cognitive and/or personality changes; later, the face becomes puffy and the facial expression dull.
Free thyroxine (T4) level is always low, but triiodothyronine (T3) may remain normal early in some disorders.
Serum TSH is the best diagnostic test.
Oral T4 (l-thyroxine) is the preferred treatment and is given in the lowest dose that restores serum TSH levels to the midnormal range.
Myxedema coma is a life-threatening complication that requires rapid diagnosis and treatment.
Screening for hypothyroidism is warranted in select populations (eg, older patients) in which it is relatively more prevalent, especially because its manifestations can be subtle.
Drugs Mentioned In This Article
|Drug Name||Select Trade|
|No US brand name|